LRCH4 (leucine rich repeats and calponin homology domain containing 4) is a regulatory protein involved in innate immune signaling and cellular proliferation with emerging roles in cancer pathogenesis. While the canonical function describes LRCH4 as an accessory protein regulating toll-like receptor signaling and lipid raft organization, recent evidence reveals its importance in cancer biology and immune cell responses. In colorectal cancer, LRCH4 is the top gene associated with unfavorable prognosis 1. Mechanistically, LRCH4 knockdown inhibits cancer cell proliferation, migration, and invasion by suppressing YAP and TGF-β/Smad signaling pathways while regulating epithelial-mesenchymal transition and extracellular matrix remodeling 1. LRCH4 was differentially expressed across CRC stages 2 and serves as a prognostic biomarker in acute myeloid leukemia, where high expression correlates with decreased mortality 3. LRCH4 has also been identified as a disease-associated protein in high-dimensional proteomic analyses of leukemia 4. Beyond cancer, LRCH4 expression is upregulated in neutrophil-derived extracellular vesicles during severe asthma exacerbation 5 and is modulated by bacterial lipopolysaccharide exposure in platelets 6. These findings position LRCH4 as a novel therapeutic target across multiple disease contexts.